Evaluation of early myocardial injury in patients with high risk of anthracycline chemotherapy by cardiac magnetic resonance imaging

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039453

Enrollment

Unknown

Registered

2020-10-28

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early myocardial injury induced by anthracycline

Interventions

1:Take cardiac-protective drugs such as ACEI/ARB, ß-blocker

2:Take cardiac-protective drugs such as ACEI/ARB, ß-blocker

Eligibility

Sex/Gender

All

Age

25 Years to 85 Years

Inclusion criteria

Inclusion criteria: It is recommended that patients with cancer who meet any of the following criteria should be considered at increased risk for developing cardiac dysfunctionTreatment that includes any of the following: 1. High-dose anthracycline (eg, doxorubicin >= 250 mg/m2, epirubicin >= 600 mg/m2); 2. High-dose radiotherapy (>= 30 Gy) where the heart is in the treatment field; 3. Lower-dose anthracycline (eg, doxorubicin = two risk factors), including smoking, hypertension, diabetes, dyslipidemia, and obesity, during or after completion of therapy; Older age ( >= 60 years) at cancer treatment; Compromised cardiac function (eg, borderline low left ventricular ejection fraction [50% to 55%], history of myocardial infarction, moderate valvular heart disease) at any time before or during treatment; 5. Treatment with lower-dose anthracycline (eg, doxorubicin < 250 mg/m2, epirubicin < 600 mg/m2) followed bytrastuzumab (sequential therapy).

Exclusion criteria

Exclusion criteria: 1. Aged 85 years; 2. Severe cardiac insufficiency (cardiac function grade III or above) detected before admission; 3. Baseline ejection fraction < 50%, systolic blood pressure < 110 mmHg, pulse < 60 beats / min; 4. ACEI / ARB and ß - receptor blockers have been used; 5. ACEI / ARB, ß - blocker is contraindicated; 6. CMR contraindications (non diamagnetic pacemaker, implantable cardioverter defibrillator, claustrophobia, etc.); 7. Poor image quality affects the analyst; 8. Severe liver and kidney dysfunction and other serious life-threatening conditions.

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiovascular Events;	—

Countries

China

Contacts

Public ContactZhong Zuo

The First Afilliated Hospital of Chongqing Medical University

zzuo-cq@Hotmail.com+86 13002366789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026